SG10201604467PA - Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy - Google Patents

Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Info

Publication number
SG10201604467PA
SG10201604467PA SG10201604467PA SG10201604467PA SG10201604467PA SG 10201604467P A SG10201604467P A SG 10201604467PA SG 10201604467P A SG10201604467P A SG 10201604467PA SG 10201604467P A SG10201604467P A SG 10201604467PA SG 10201604467P A SG10201604467P A SG 10201604467PA
Authority
SG
Singapore
Prior art keywords
cadherin
extracellular domain
cancer therapy
related methods
soluble extracellular
Prior art date
Application number
SG10201604467PA
Other languages
English (en)
Inventor
Sabine Brouxhon
M Kerry O'banion
Stephanos Kyrkanides
Original Assignee
Univ New York State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ New York State Res Found filed Critical Univ New York State Res Found
Publication of SG10201604467PA publication Critical patent/SG10201604467PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4703—Regulators; Modulating activity
    • G01N2333/4704—Inhibitors; Supressors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Optics & Photonics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
SG10201604467PA 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy SG10201604467PA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US40736710P 2010-10-27 2010-10-27

Publications (1)

Publication Number Publication Date
SG10201604467PA true SG10201604467PA (en) 2016-07-28

Family

ID=45994754

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201604467PA SG10201604467PA (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
SG2013032875A SG189547A1 (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
SG10202100921YA SG10202100921YA (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Family Applications After (2)

Application Number Title Priority Date Filing Date
SG2013032875A SG189547A1 (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
SG10202100921YA SG10202100921YA (en) 2010-10-27 2011-10-27 Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy

Country Status (13)

Country Link
US (4) US20130287784A1 (https=)
EP (1) EP2632489B1 (https=)
JP (1) JP6243737B2 (https=)
KR (1) KR20140075639A (https=)
CN (1) CN103582494A (https=)
AU (1) AU2011319777B2 (https=)
BR (1) BR112013010535A2 (https=)
CA (1) CA2816358A1 (https=)
ES (1) ES2784385T3 (https=)
MX (2) MX357167B (https=)
RU (1) RU2013123792A (https=)
SG (3) SG10201604467PA (https=)
WO (1) WO2012058418A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9534058B2 (en) 2012-02-08 2017-01-03 Abbvie Stemcentrx Llc Anti-CD324 monoclonal antibodies and uses thereof
EP2844270A4 (en) * 2012-03-15 2016-01-27 Univ New York State Res Found COMBINATION THERAPIES WITH INHIBITORS OF THE EXTRACELLULAR DOMAIN OF E-CADHERINE
US9411750B2 (en) 2012-07-30 2016-08-09 International Business Machines Corporation Efficient calibration of a low power parallel data communications channel
US9474034B1 (en) 2015-11-30 2016-10-18 International Business Machines Corporation Power reduction in a parallel data communications interface using clock resynchronization
US10492104B2 (en) * 2016-03-10 2019-11-26 Cable Television Laboratories, Inc. Latency reduction in wireless service
CN109076413B (zh) 2016-03-10 2021-09-28 有线电视实验室公司 用于等待时间减少的系统和方法
US10321351B2 (en) 2017-03-02 2019-06-11 Cable Television Laboratories, Inc. System and method for grant assignment
US10738127B2 (en) 2016-06-10 2020-08-11 Veritas Biotecnologia Ltda Monoclonal antibodies prevent cell surface protein shedding and block tumor growth
US10420085B2 (en) 2016-10-07 2019-09-17 Cable Television Laboratories, Inc. System and method for grant assignment
US12225536B2 (en) 2016-10-07 2025-02-11 Cable Television Laboratories, Inc. System and method for grant assignment
US10825479B2 (en) 2018-05-11 2020-11-03 Axon Enterprise, Inc. Systems and methods for cross-redaction
US20240317880A1 (en) * 2020-01-10 2024-09-26 Kling Biotherapeutics B.V. Epithelial Cadherin-Specific Antibodies

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4196265A (en) 1977-06-15 1980-04-01 The Wistar Institute Method of producing antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
KR940009084B1 (ko) 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
AU4128089A (en) 1988-09-15 1990-03-22 Rorer International (Overseas) Inc. Monoclonal antibodies specific to human epidermal growth factor receptor and therapeutic methods employing same
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5667988A (en) 1992-01-27 1997-09-16 The Scripps Research Institute Methods for producing antibody libraries using universal or randomized immunoglobulin light chains
EP1306095A3 (en) 1992-03-05 2003-06-25 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US6004555A (en) 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US6093399A (en) 1992-03-05 2000-07-25 Board Of Regents, The University Of Texas System Methods and compositions for the specific coagulation of vasculature
US5877289A (en) 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
AU5669494A (en) * 1992-11-17 1994-06-08 Yale University Human homolog of the e-cadherin gene and methods based thereon
DE614989T1 (de) 1993-02-17 1995-09-28 Morphosys Proteinoptimierung Verfahren für in vivo Selektion von Ligandenbindende Proteine.
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US5702892A (en) 1995-05-09 1997-12-30 The United States Of America As Represented By The Department Of Health And Human Services Phage-display of immunoglobulin heavy chain libraries
US6723320B2 (en) * 1996-07-24 2004-04-20 Gsf Forschungszentrum Fur Umwelt Und Geshundheit Gmbh Mutations of E cadherin as a basis for the diagnosis and therapy of human malignant tumors
US6015557A (en) 1999-02-24 2000-01-18 Tobinick; Edward L. Tumor necrosis factor antagonists for the treatment of neurological disorders
AU2002226075A1 (en) * 2000-10-23 2002-05-06 University Of Kansas Cadherin peptides for drug delivery and inhibition of tumor metastasis/invasion
CA2441626A1 (en) 2001-03-28 2002-10-17 Children's Medical Center Corporation Fusion protein construct and method for inducing hiv-specific serum igg and secretory iga antibodies in-vivo
US7074175B2 (en) 2001-07-25 2006-07-11 Erik Schroeder Handy Thermotherapy via targeted delivery of nanoscale magnetic particles
US6997863B2 (en) 2001-07-25 2006-02-14 Triton Biosystems, Inc. Thermotherapy via targeted delivery of nanoscale magnetic particles
US20060239970A1 (en) 2003-01-23 2006-10-26 Federoff Howard J Herpesvirus amplicon particles
US8455249B2 (en) * 2009-05-01 2013-06-04 The University Of Tokyo Highly effective anti-cadherin antibody for induction of antibody-dependent cellular cytotoxicity in vivo

Also Published As

Publication number Publication date
JP6243737B2 (ja) 2017-12-06
MX357167B (es) 2018-06-28
US20160046701A1 (en) 2016-02-18
WO2012058418A3 (en) 2012-07-19
MX2013004790A (es) 2014-01-17
EP2632489A4 (en) 2014-06-18
US20130287784A1 (en) 2013-10-31
BR112013010535A2 (pt) 2017-11-07
SG189547A1 (en) 2013-05-31
CA2816358A1 (en) 2012-05-03
JP2014500862A (ja) 2014-01-16
SG10202100921YA (en) 2021-03-30
US20190352380A1 (en) 2019-11-21
ES2784385T3 (es) 2020-09-24
US20210380671A1 (en) 2021-12-09
WO2012058418A2 (en) 2012-05-03
MX2018007983A (es) 2023-02-23
KR20140075639A (ko) 2014-06-19
AU2011319777A1 (en) 2013-05-23
RU2013123792A (ru) 2014-12-10
EP2632489A2 (en) 2013-09-04
CN103582494A (zh) 2014-02-12
EP2632489B1 (en) 2020-01-15
AU2011319777B2 (en) 2016-12-08

Similar Documents

Publication Publication Date Title
SG10202100921YA (en) Compositions targeting the soluble extracellular domain of e-cadherin and related methods for cancer therapy
ZA201300567B (en) Methods and compositions for liver cancer therapy
SG10201509279QA (en) Compositions and methods for the prevention and treatment of cancer
DK2608777T3 (en) Compositions and Methods for Cardiac Therapy
EP2521553A4 (en) METHODS AND COMPOSITIONS FOR THE DEVELOPMENT OF TARGETED MEDICAMENTS
SG10201500124VA (en) Methods and Compositions for Treating Cancer
IL251083A0 (en) Compounds and preparations for the treatment of cancer
EP2526118A4 (en) COMPOSITIONS AND METHOD FOR THE TREATMENT OF EGG CANCER
IL238177A0 (en) Methods and preparations for the treatment of cancer
IL222739A0 (en) Methods of use soluble cd24 for therapy of rhematoid arthritis
IL224186A (en) Human antibodies are targeted to Cadrin-11's ec1 domain and related preparations and methods
PL2605764T3 (pl) Kompozycje do leczenia nowotworu
IL226095A0 (en) The history of pyridine and its use in pharmaceutical preparations for the treatment of cancer
AP3480A (en) Phosphaplatins and their use for treatment of cancers
EP2646042A4 (en) CYTOTOXIC TUMOR ACTIVE SUBSTANCE AND METHOD THEREFOR
IL226252B (en) Combination of fgfr1 extracellular site and another factor for cancer treatment
WO2011130697A3 (en) Tissue targeting
PL2619331T3 (pl) Sposoby leczenia nowotworu obejmujące ukierunkowanie na nqo1
EP2522366A4 (en) OBJECTIVE FOR TUMOR PLACES
WO2012003421A9 (en) Combinational compositions and methods for treatment of cancer
ZA201407213B (en) Efficient synthesis of ethylenedicysteine-sugar conjugates for imaging and therapy
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
HK1189502A (en) Compositions and methods for the prevention and treatment of cancer
HK1178547A (en) Compositions and methods for treatment of ovarian cancer
HK1189801A (en) Novel compositions and uses of anti-hypertension agents for cancer therary